Suppr超能文献

肢体软组织肉瘤生存和局部复发的预后预测因素。

Prognostic factors predictive of survival and local recurrence for extremity soft tissue sarcoma.

作者信息

Singer S, Corson J M, Gonin R, Labow B, Eberlein T J

机构信息

Department of Surgery, Brigham & Women's Hospital/Harvard Medical School, Boston, Massachusetts.

出版信息

Ann Surg. 1994 Feb;219(2):165-73. doi: 10.1097/00000658-199402000-00008.

Abstract

OBJECTIVE

The authors sought to identify prognostic factors in the management of extremity soft tissue sarcoma.

SUMMARY BACKGROUND DATA

The surgical management of soft tissue sarcoma has evolved because of advances in therapy, resulting in increased limb preservation and quality of life. However, identifying a subset of patients most likely to benefit from adjuvant chemotherapy has been difficult to achieve.

METHODS

A retrospective analysis of a prospective data base of 182 patients with extremity sarcomas from 1970 to 1992 was performed.

RESULTS

A histologic diagnosis of Ewing's sarcoma, synovial sarcoma, and angiosarcoma was associated with a 13-fold increased risk of death compared with liposarcoma, fibrosarcoma, and malignant peripheral nerve sheath histologic types after having adjusted for the other prognostic factors (p < 0.001). In addition to histologic type, high-grade sarcomas (p = 0.018), sarcomas greater than 10 cm in size (p = 0.006), and age at diagnosis (p = 0.016) were found to be important prognostic factors for survival but not for local recurrence. For the first time to their knowledge, the authors showed that mean mitotic activity has prognostic value after having adjusted for other prognostic factors, such as grade (p = 0.005). The only prognostic factors predictive for local recurrence were whether the patient presented with locally recurrent disease (p = 0.0001) or had microscopically positive margins (p = 0.052).

CONCLUSIONS

The use of mitotic activity along with grade, size, histologic type, and age at diagnosis is prognostic for survival in extremity soft tissue sarcoma. The use of an objective pathologic feature, such as mean mitotic activity, is also useful in selecting patients for future systemic neoadjuvant or adjuvant trials and primary therapy.

摘要

目的

作者试图确定肢体软组织肉瘤治疗中的预后因素。

总结背景资料

由于治疗方法的进步,软组织肉瘤的外科治疗得到了发展,从而提高了肢体保留率和生活质量。然而,确定最有可能从辅助化疗中获益的患者亚组一直难以实现。

方法

对1970年至1992年182例肢体肉瘤患者的前瞻性数据库进行回顾性分析。

结果

在对其他预后因素进行校正后,与脂肪肉瘤、纤维肉瘤和恶性外周神经鞘瘤组织学类型相比,尤因肉瘤、滑膜肉瘤和血管肉瘤的组织学诊断与死亡风险增加13倍相关(p < 0.001)。除组织学类型外,高级别肉瘤(p = 0.018)、大小大于10 cm的肉瘤(p = 0.006)和诊断时的年龄(p = 0.016)被发现是生存的重要预后因素,但不是局部复发的预后因素。据作者所知,他们首次表明,在对其他预后因素如分级进行校正后,平均有丝分裂活性具有预后价值(p = 0.005)。预测局部复发的唯一预后因素是患者是否存在局部复发性疾病(p = 0.0001)或镜下切缘阳性(p = 0.052)。

结论

将有丝分裂活性与分级、大小、组织学类型和诊断时的年龄结合使用可预测肢体软组织肉瘤的生存情况。使用客观的病理特征,如平均有丝分裂活性,也有助于选择患者进行未来的全身新辅助或辅助试验及初始治疗。

相似文献

5
Modified staging system for extremity soft tissue sarcomas.肢体软组织肉瘤改良分期系统。
Ann Surg Oncol. 1999 Jan-Feb;6(1):57-69. doi: 10.1007/s10434-999-0057-9.
8
The influence of local recurrence of extremity soft tissue sarcoma on metastasis and survival.
Cancer. 1990 Mar 1;65(5):1119-29. doi: 10.1002/1097-0142(19900301)65:5<1119::aid-cncr2820650515>3.0.co;2-p.

引用本文的文献

2
Outcome of Soft Tissue Popliteal Sarcomas: 15 Years of Experience.腘窝软组织肉瘤的治疗结果:15年经验总结
Indian J Orthop. 2024 Sep 25;59(1):34-39. doi: 10.1007/s43465-024-01263-8. eCollection 2025 Jan.

本文引用的文献

3
Adjuvant chemotherapy for patients with soft tissue sarcomas.
Surg Clin North Am. 1981 Dec;61(6):1415-23. doi: 10.1016/s0039-6109(16)42595-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验